Business
Medicus Pharma on Bloomberg World
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life ...
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller","length":100,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Matt Miller from Bloomberg World for a live interview on February 10, 2026. https://youtu.be/2-naOb7uJRc?si=eumsbejKNkAdQ62G","length":453,"tagName":"p"},{"id":"2-naOb7uJRc","subtype":"videoIframe","allowFullScreen":"","type":"youtube","url":"https://www.youtube.com/embed/2-naOb7uJRc","width":854,"height":480,"anchorId":"9cc023aa-d822-597f-a41e-af6537192191"},{"type":"text","content":"In this live interview on Bloomberg World, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, discusses the company's strategy, the challenges facing biotech stocks, and how artificial intelligence is shaping its drug development efforts.","length":255,"tagName":"p"},{"type":"text","content":"Central to the discussion is the role of AI in accelerating drug development. Dr. Bokhari outlines Medicus Pharma's AI-driven approach, positioning the company's leadership as both. investors and operators that have committed nearly $14 million of personal capital at $4 per share toward advancing its pipeline. He expresses confidence in his beliefs that continued AI-enabled progress, regulatory optionality, and upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, should materially change investor perception and unlock value, in the same manner it did in the first half of 2025, following the of a positively trending interim data analysis.","length":701,"tagName":"p"},{"type":"text","content":"The conversation underscores both the short-term volatility in biotech markets and the company's long-term belief in the potential of AI to transform innovative therapy development.","length":185,"tagName":"p"},{"type":"text","content":"Click here to watch the full interview.","length":39,"tagName":"p"},{"type":"text","content":"For further information contact:","length":32,"tagName":"p"},{"type":"text","content":"Carolyn...